XW043B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3

New Technology›Anatomical Regions›Introduction

Billable / Specific Code

ICD-10-PCS XW043B3

CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.

XW043B3 is a billable ICD-10-PCS procedure code for Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Code Identity

ICD-10-PCS Code

XW043B3

Billable Status

Yes — Valid for Submission

Code Describes

Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3

Parent Code

XW0

Short Description

Introduce cytarab/daunorub in Central Vein, Perc, New Tech

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

Position	Designation	Value	Meaning
1	Section	X	New Technology
2	Body System	W	Anatomical Regions
3	Operation	0	Introduction
4	BodyPart	4	Central Vein
5	Approach	3	Percutaneous
6	Device/Substance/Technology	B	Cytarabine and Daunorubicin Liposome Antineoplastic
7	Qualifier	3	New Technology Group 3

Convert to ICD-9-PCS

Closest ICD-9-PCS equivalents for XW043B3 under the General Equivalence Mappings.

99.25

Approximate match.

Code History

Replaces previously assigned code(s):

3E04305 — Introduce Oth Antineoplastic in Central Vein, Perc

Similar Procedure Codes

Filter related codes list:

Questions About XW043B3

Is XW043B3 a billable code?

Yes. XW043B3 is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW043B3 mean?

XW043B3 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character B is the Device/Substance/Technology (Cytarabine and Daunorubicin Liposome Antineoplastic); the 7th character 3 is the Qualifier (New Technology Group 3).

What is the ICD-9-PCS equivalent of XW043B3?

Under the General Equivalence Mappings, Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3 crosswalks to ICD-9-PCS 99.25. The mapping is approximate, so confirm it fits the documentation.